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        Hodgkin lymphoma (HL), one of the most 
common malignant lymphomas, comprises two 
entities, classical HL (cHL) and nodular lympho-
cyte  –  predominant HL (NLPHL). The tumor 
cells     Hodgkin and Reed/Sternberg (HRS) cells 
in cHL and lymphocytic and histiocytic (L  &  H) 
cells in NLPHL     usually represent   <  1% of cells 
in the tumor, being dispersed in a prominent 
infl  ammatory cellular background. Tumor cells 
of both entities are derived from germinal cen-
ter (GC) B cells, but they are genetically, mor-
phologically, and phenotypically diff  erent. HRS 
cells often carry   “  crippling  ”   mutations in origi-
nally functional IgV gene rearrangements and, 
thus, likely derive from preapoptotic GC B cells 
(  1  ). The process of somatic hypermutation is 
silenced in these cells. HRS cells lack expression 
of most B cell molecules (  2  ) and express mark-
ers typical for other hematopoietic lineages (  1  ). 
L  &  H cells, on the other hand, express func-
tional IgV genes and often show intraclonal V 
gene diversifi  cation (  1  ), a feature they share with 
normal GC B cells. Also immunohistochemically, 
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  The pathogenesis of nodular lymphocyte  –  predominant Hodgkin lymphoma (NLPHL) and its 
relationship to other lymphomas are largely unknown. This is partly because of the techni-
cal challenge of analyzing its rare neoplastic lymphocytic and histiocytic (L  &  H) cells, which 
are dispersed in an abundant nonneoplastic cellular microenvironment. We performed a 
genome-wide expression study of microdissected L  &  H lymphoma cells in comparison to 
normal and other malignant B cells that indicated a relationship of L  &  H cells to and/or 
that they originate from germinal center B cells at the transition to memory B cells. L  &  H 
cells show a surprisingly high similarity to the tumor cells of T cell  –  rich B cell lymphoma 
and classical Hodgkin lymphoma, a partial loss of their B cell phenotype, and deregulation 
of many apoptosis regulators and putative oncogenes. Importantly, L  &  H cells are charac-
terized by constitutive nuclear factor     B activity and aberrant extracellular signal-regu-
lated kinase signaling. Thus, these fi  ndings shed new light on the nature of L  &  H cells, 
reveal several novel pathogenetic mechanisms in NLPHL, and may help in differential 
diagnosis and lead to novel therapeutic strategies. 
© 2008 Brune et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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nant lymphomas and the normal B cell subsets, respectively. 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20080809/DC1). Among the latter, three main subbranches 
separate plasma cells and resting peripheral blood cells (naive 
and memory B cells) from GC B cells. To better determine 
the relatedness of L  &  H cells to the other lymphomas, un-
supervised clustering was restricted to the tumor samples 
(  Fig. 1  ).   FLs and BLs clustered separately from each other in 
one branch of the dendrogram, which also comprised the 
majority of DLBCLs (6 out of 11) and 1 TCRBL. NLPHLs 
clustered in the other branch, close to most TCRBLs (3 out 
of 4) and some DLBCLs (3 out of 11) and cHLs. The L  &  H 
profi  les were more similar to each other than to any other 
B cell lymphoma, implying that NLPHL represents a distinct 
entity among the B cell lymphomas analyzed. In contrast, 
DLBCLs, which are known to be composed of more than one 
subentity (  15, 16  ), did not form a separate branch but were 
intermingled with other lymphomas. 
  We next examined the relationship of L  &  H cells with 
other lymphomas by principal component analysis (PCA) of 
the mean expression vectors of each entity (  Fig. 2 A  ).   NLPHL 
showed a closer relatedness to TCRBL and cHL than to 
DLBCL, BL, or FL, which was in line with the results of the 
unsupervised hierarchical clustering (  Fig. 1  ). 
  Close relatedness of L  &  H and HRS cells is confi  rmed 
by supervised analysis 
  In a supervised comparison between the profi  les of L  &  H and 
HRS cells, only 43 genes were diff  erentially expressed (  ≥  1.8 
fold change [FC]) in a statistically signifi  cant manner (false 
discovery rate [FDR]   <   0.05 after the   t   test; unpublished data). 
Notably, applying the same fi  lter criteria, approximately sev-
enfold more (295) genes turned out to distinguish NLPHL from 
FL (unpublished data), which resembles NLPHL in various 
  aspects. Because cHLs are often heterogeneous in their ex-
pression of immunohistological markers (  17  ), we relaxed the 
FDR fi  lter to   <  0.1 and revealed 129 genes diff  erentially ex-
pressed between NLPHL and cHL, of which 6 were expressed 
at higher levels in HRS cells and 123 were expressed at higher 
levels in L  &  H cells. 
  Three of the six genes up-regulated in cHL, namely the 
chemokines   CCL22   (  MDC  ) and   CCL17   (  TARC  ), and   IL6  , 
are known to be expressed in HRS cells more frequently 
and/or at higher levels than in L  &  H cells (  18  –  20  ), thus vali-
dating our analysis. High expression of the Jun dimerization 
protein p21SNFT is also known for HRS cells (  21  ). 
  Other genes known to be diff  erentially expressed be-
tween HRS and L  &  H cells, e.g.,   CD30   and   GATA3  , were 
not found. This is because their mRNA expression levels 
in the cHL cases were too heterogeneous to fulfi  ll the fi  l-
ter criteria. 
  Most of the 123 genes up-regulated in L  &  H cells are ex-
pressed at similar levels in GC B cells, indicating that these 
are (GC) B cell genes down-regulated in HRS cells. Thus, 
only 27 genes remain that are up-regulated in L  &  H cells com-
pared with HRS and GC B cells (  Table I  ).   
L  &  H cells resemble GC B cells, as they express BCL6 (a key 
transcription factor for the GC B cell program) (  3  ), activa-
tion-induced cytidine deaminase (the enzyme critical for so-
matic hypermutation and class switching in GC B cells) (  4  ), 
and the GC B cell markers human GC-associated lymphoma 
(  5  ) and centerin (  6  ). However, L  &  H cells frequently lack 
expression of some pan  –  B lineage markers, e.g., CD19, and 
the GC markers CD10 and PAG (  7  –  9  ). GC and NLPHL also 
resemble each other in their follicular growth pattern and in 
their association with follicular dendritic cells and CD57  +   T 
helper cells. Many of these features of NLPHL are observed 
in follicular lymphoma (FL), too, suggesting a close relation-
ship between these lymphomas (  10  ). 
  Only very little is known about the pathogenetic mecha-
nisms in NLPHL. Comparative genomic hybridization analysis 
revealed the occurrence of recurrent but nonspecifi  c chro-
mosomal abnormalities in NLPHL (  11  ). Approximately 50% 
of NLPHLs harbor BCL6 oncogene rearrangements (  12, 13  ). 
Moreover, various protooncogenes are targeted by aberrant 
somatic hypermutation in L  &  H cells, which may alter the 
function of these genes and thereby contribute to NLPHL 
pathogenesis (  14  ). 
  Because of the extraordinary technical diffi   culties in analyz-
ing tumor cells present in tissues in such a small amount, no 
systematic large-scale gene expression study of L  &  H cells has 
been performed so far. In this study, we succeeded in estab-
lishing a reliable method to microdissect primary L  &  H cells 
from frozen tissue sections, isolating RNA from the cells and 
analyzing their global gene expression after a two-rounded 
in vitro transcription. This allowed us to clarify the following 
questions: (a) does the gene expression profi  le of L  &  H cells 
defi  ne NLPHL as a distinct entity; (b) what is the histoge-
netic origin of L  &  H cells; (c) to which other malignant B cells 
are L &  H cells most closely related in terms of gene expression; 
(d) can we identify L  &  H cell  –  specifi  c genes that might be in-
volved in the pathogenesis of NLPHL and represent potential 
new diagnostic markers or therapeutic targets; and (e) which 
signaling pathways are active in L  &  H cells that could pro-
mote their growth and survival? 
    RESULTS   
  Gene expression profi  ling of isolated L  &  H cells defi  nes 
NLPHL as a distinct entity closely related 
to T cell  –  rich B cell lymphoma (TCRBL), a subset 
of diffuse large B cell lymphoma (DLBCL), and cHL 
  Using Aff  ymetrix U133 Plus 2.0 microarrays (representing 
    47,000 transcripts), gene expression profi  les were generated 
from microdissected L  &  H cells of fi  ve cases of NLPHL and 
compared with the main subsets of normal B cells (CD77  +   
and CD77         GC B cells and plasma cells isolated from ton-
sils, and naive and memory B cells isolated from peripheral 
blood; 5 donors each), with tumor cells of B cell non-HLs 
(B-NHLs; 5 FLs, 5 Burkitt lymphomas [BLs], 11 DLBCLs, 
and 4 TCRBLs, a rare variant of DLBCL), and with HRS 
cells of 12 cHLs. Unsupervised hierarchical clustering divided 
the 67 profi  les into two main branches comprising the malig-JEM VOL. 205, September 29, 2008 
ARTICLE
2253
include the transcription factors  EOMES  , the cathepsins  CTSB   
and  CTSK  , matrix metalloprotease 12 ( MMP12  ), a member of 
the tumor protein family D52 (  TPD52L1  ), a member of the 
Ras oncogene family (  RAS42  ), the protooncogene   CTTN  , 
the serine/threonine kinase   PRKCZ  , vascular cell adhesion 
molecule 1 (  VCAM1  ),   KISS1R  , and insulin-like growth fac-
tor 2 receptor (  IGF2R  ). The fi  ve genes down-regulated in L  &  H 
cells represent B lineage  –  specifi  c genes (  Table II  ). 
  L  &  H cells show a similar relatedness to GC 
and memory B cells 
  To identify the closest normal counterpart of L  &  H cells, PCA 
was performed using genes diff  erentiating GC B cells from 
naive B cells, memory B cells, or plasma cells, and memory B 
cells from naive B cells or plasma cells (  Fig. 2 B  ). In the com-
parisons of GC B cells to naive B cells and plasma cells, L  &  H 
cells were more similar to GC B cells. L  &  H cells were also 
more similar to memory B cells than to plasma cells. How-
ever, when compared with GC B cells and memory B cells, 
L  &  H cells were equidistant from both. This, together with 
the much higher similarity of L  &  H cells to memory than to 
naive B cells (  Fig. 2 B  ), suggests that L  &  H cells resemble an 
intermediate developmental stage in the transition between 
GC B cells and memory B cells. 
  Comparison of L  &  H cells to GC B cells 
  To investigate whether there are deregulated signaling path-
ways in L  &  H cells that promote their growth and survival, we 
compared the L  &  H cell profi  les with those of their nonmalig-
nant B cell counterparts. We selected GC B cells for this analy-
sis, although the PCA also indicated some similarity of L  &  H 
cells to memory B cells, because the overall features of L  &  H 
cells (a GC-like growth pattern, the expression of key GC 
B cell factors, and ongoing hypermutation) strongly support a 
GC B cell origin of L  &  H cells. We identifi  ed 963 diff  erentially 
expressed genes (558 up-regulated and 405 down-regulated in 
L  &  H cells; FDR   ≤   0.05 after the   t   test; FC   ≥   1.8; unpublished 
data). Several of the up-regulated genes are known for their 
  Up-regulation of these genes in L  &  H as compared with 
HRS cells is mostly moderate (two- to threefold). Among 
them, we identifi  ed KISS1 receptor (  KISS1R  ), SLAM family 
member 7 (  SLAMF7  ), protein kinase C      , and serum/gluco-
corticoid-regulated kinase (  SGK  ). Collectively, we identifi  ed 
surprisingly few genes that showed consistent diff  erences in 
expression between HRS and L  &  H cells. 
  Only a few genes distinguish L  &  H cells from lymphoma cells 
of TCRBL 
  The supervised comparison of L  &  H cells and the lymphoma 
cells of TCRBL, a highly heterogenous entity (  22  ), revealed 
42 genes consistently diff  erentially expressed (FC   ≥   1.8; P   <   
0.05 using the   t   test; FDR   <   0.2; Fig. S2 and Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20080809/DC1). 
All 42 genes showed enhanced expression in L  &  H cells com-
pared with TCRBL and include autotaxin (  ENPP2  ), the pro-
tooncogene cortactin (  CTTN  ), and       kinase 2 (  ALPK2  ). 
  Identifi  cation of   “  L  &  H cell  –  specifi  c  ”   genes 
  To identify genes specifi  cally up- or down-regulated in L  &  H 
cells, a supervised comparison of the NLPHL profi  les with 
those of the normal B cells and B-NHL was performed. The 
12 cHL profi  les were not included because the high similar-
ity between NLPHL and cHL in terms of gene expression 
would bias the analysis, as they represent one third of all lym-
phoma samples. 49 genes are consistently up-regulated in the 
L  &  H cells, and 5 genes are down-regulated (  Table II  ; and 
Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20080809/DC1).   The expression pattern of several of the 
54 genes in NLPHL is relatively similar to that observed in 
the same TCRBLs and DLBCLs (TCRBLs 1, 2, and 4, and 
DLBCL 2, 3, and 11) that cluster near the L  &  H cell profi  les 
in the unsupervised hierarchical clustering (  Fig. 1  ), consistent 
with the reported biological and phenotypical relatedness of 
these lymphomas. 
  Notably, the genes up-regulated in L  &  H cells have not 
been previously described to be expressed in these cells. They 
    Figure 1.         Unsupervised hierarchical clustering of lymphoma samples.   The dendrogram is based on the expression data of the 582 most variable 
genes (BL, black; cHL, red; DLBCL, dark blue; FL, light blue; NLPHL, orange; TCRBL, green).     2254 NODULAR LYMPHOCYTE  –  PREDOMINANT HODGKIN LYMPHOMA   | Brune et al. 
tors   BAFF   (  TNFSF13B  ; 10.5-fold up-regulated) and   APRIL   
(  TNFSF13  ; 4.5-fold up-regulated), and the transcription fac-
tors   STAT1   and   STAT2   (17.7-/8.7-/6.4-fold and 1.8-fold 
up-regulated, respectively) and   EOMES   (4.1-fold up-regu-
lated). A direct target of EOMES, IL2RB (CD122) (  29  ), is 
also 7.4-fold up-regulated.      -2 microglobulin (  B2M  ), which is 
up-regulated by STAT1 and is part of MHC I, is fi  vefold up-
regulated in L  &  H cells. STAT1 can promote leukemia develop-
ment by maintaining high MHC I expression (  30  ). 
expression in L  &  H cells, i.e., RAS family member   RAB13   
(  23  ), EBV-induced gene 3 (  EBI3  ) (  24  ), TNF-       –  induced pro-
tein 3 (  TNFAIP3  ;   A20  ) (  25  ),   FYN   (  26  ),   CFLAR   (  c-FLIP  ) 
(  27  ), the chemokine ligands   CXCL9   (  MIG  ) and   CXCL10   (  IP10  ) 
(  18  ), and transferrin receptor (  TFRC; CD71  ) (  28  ) (see   Fig. 4  ; 
Fig. S4, available at http://www.jem.org/cgi/content/full/jem
.20080809/DC1; and not depicted). 
  The other up-regulated genes, previously not reported 
to be expressed in L  &  H cells, include the B cell survival fac-
    Figure 2.         Relatedness of L  &  H cells with other lymphomas and with normal B cells by PCA.   (A) 3,364 genes, whose median expression was above 
background in at least one lymphoma entity, were used by PCA to assess the relatedness of L  &  H cells (mean of 5 samples) to the malignant B cells of other 
lymphomas (mean of 4  –  12 samples). The fi  rst two principal components are shown (accounting for 88.1% and 5.5% of the total variance, respectively). 
(B) Genes discriminating between GC B cells and naive B (N), memory B (M), or plasma cells (PC; FC   ≥   4; FDR   <   0.05 after   t   test; 229, 128, and 130 probe sets), 
and between naive and memory B cells (FC   ≥   2.5; FDR   <   0.05 after   t   test; 47 probe sets) or between memory B cells and plasma cells (FC   ≥   4; FDR   <   0.05 
after   t   test; 135 probe sets) were used by PCA to identify the closest normal counterpart of L  &  H cells. In each of the fi  ve graphs, the y axis indicates the fi  rst 
principal component score, the horizontal solid lines show the median score of each cell subset, and the horizontal dotted line represents the mean of the 
median scores of the two normal subsets being compared. Also shown are the p-values (obtained by   t   test) of the pairwise comparisons (vertical lines) be-
tween L  &  H cells and normal B cells. The percentage of total variance accounted for by the fi  rst principal component is as follows: GC B versus plasma cells, 
89%; GC B versus na  ï  ve B cells, 93.9%; GC B versus memory B cells, 92.5%; memory versus na  ï  ve B cells, 86.6%; and memory B versus plasma cells, 92.8%.     JEM VOL. 205, September 29, 2008 
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nine protein kinase, acts as an oncogene in breast cancer cells 
through activation of NF-     B (  31  ). Cortactin is overexpressed 
in several cancers and contributes to tumor cell invasiveness 
and metastasis (  32  ). Additionally, several members of the Ras 
oncogene family, i.e., RAB13, RAB20, RAB27A, RAB42, 
  Among the genes diff  erentially expressed between L  &  H 
and GC B cells, several up-regulated genes have known onco-
genic potential, namely   FYN  ,   SGK  , and   CTTN   (each about 
threefold up-regulated). The protein-tyrosine kinase FYN is 
implicated in the control of cell growth. SGK, a serine/threo-
    Table I.        Genes differentially expressed between NLPHL and cHL 
FC Gene  
  symbol
Affymetrix probe set ID Gene name
Genes up-regulated in cHL  
  compared with NLPHL
33.6   CCL22  207861_at chemokine (c-c motif) ligand 22; MDC
15.6   CCL17  207900_at chemokine (c-c motif) ligand 17; TARC
7.2   SNFT  220358_at Jun dimerization protein p21SNFT
4  ODZ2  231867_at odz, odd Oz/ten-m homolog 2 (  Drosophila  ); 
teneurin-2
3.1   IL6 205207_at IL-6 (IFN,       2)
2.3   MGST3  201403_s_at microsomal glutathione S-transferase 3
Genes up-regulated in NLPHL 
compared with cHL (and GC B cells)
4.9   KISS1R  242517_at KISS1 receptor; GPR54
3.9   CHIT1  208168_s_at chitinase 1 (chitotriosidase)
3.9/2.9   GBP1 231577_s_at 
              202269_x_at
guanylate binding protein 1, IFN-inducible, 67 kD
3.8   SGK 201739_at serum/glucocorticoid-regulated  kinase
3.2   CHI3L1  209396_s_at chitinase 3-like 1 (cartilage glycoprotein-39)
2.9   SLAMF7  222838_at SLAM family member 7
2.9   GLA 214430_at galactosidase,     
2.9   TSC22D1  215111_s_at TSC22 domain family, member 1
2.8   STAT1 AFFX-HUMISGF3A/   
              M97935_3_at
signal transducer and activator of transcription 
1, 91 kD
2.8   EOMES  231776_at eomesodermin homolog (  Xenopus laevis  )
2.8   ITM2A  202747_s_at integral membrane protein 2A
2.6   TMEM163  223503_at transmembrane protein 163
2.6   ATP6V1A 201972_at ATPase,  H  +   transporting, lysosomal 70 kD, V1 
subunit A
2.5   PLXNA1 221538_s_at plexin  A1
2.4   DRAM  218627_at damage-regulated autophagy modulator
2.4   DUSP2 204794_at Dual-specifi  c phosphatase 2; PAC1
2.4   PLEK 203471_s_at pleckstrin
2.3   CKS2  204170_s_at CDC28 protein kinase regulatory subunit 2
2.3   PRKCZ 202178_at protein kinase C,     
2.3   LIMS1  212687_at LIM and senescent cell antigen-like domains 1
2.2   F11R 223000_s_at F11  receptor
2.2   SLC31A1  203971_at solute carrier family 31 (copper transporters), 
member 1
2.1   CTSH 202295_s_at cathepsin  H
2.1   BID  211725_s_at BH3 interacting domain death agonist
2.1   NOD27  226474_at nucleotide-binding oligomerization domains 27
1.8   RAB27A  210951_x_at RAB27A, member RAS oncogene family
1.8   PSMB8 209040_s_at proteasome (prosome, macropain) subunit,       type, 
8 (large multifunctional peptidase 7)
129 genes are differentially expressed between L  &  H and HRS using   ≥  1.8 as the FC cut-off, and a   t   test p-value of   <  0.05/FDR of   <  0.1 as the statistical cut-off. Out of the 123 
genes expressed at higher levels in L  &  H than in HRS cells, only 27 are also up-regulated in comparison to GC B cells, and they are shown in this table. The remaining 96 genes 
are down-regulated in HRS cells compared with GC B cells (unpublished data).2256 NODULAR LYMPHOCYTE  –  PREDOMINANT HODGKIN LYMPHOMA   | Brune et al. 
    Table II.       L  & H  cell – specifi  c genes 
FC Gene  
  symbol
Affymetrix  
  probe set ID
Gene function
Genes up-regulated in NLPHL  
  compared with normal B cells and B-NHL
13   MMP12  204580_at matrix metalloprotease; involved in ECM degradation, 
metastasis and angiogenesis
9.8   CHIT1 208168_s_at
8.5   CTSK  202450_s_at involved in ECM degradation and tumor invasion
7.6   CYP27B1 205676_at
7.1   ZBED2 219836_at
6.7   ALPK2 228367_at
6.3 230741_at
6.2   KISS1R  242517_at involved in ERK activation; overexpressed in several cancers
5.5   RGS4  204337_at regulator of G protein signaling
5  TPD52L1  203786_s_at member of the tumor protein D52 family; involved in cell 
proliferation and calcium signaling
4.6   PLA2G7 206214_at
4.6   NPL 221210_s_at
2.9 240449_at
4.5   UBD  205890_s_at may modulate tumorigenesis; high levels of   UBD   in cells lead to 
increased mitotic nondisjunction and chromosome instability
4.5   SLC1A3 202800_at
4.3   VCAM1 203868_s_at mediates  leukocyte  –  endothelial cell adhesion
4.2   MAF  206363_at oncogene; transcription factor; overexpressed in multiple 
myelomas
4  CD2 205831_at
4  DRAM 218627_at
3.8 230391_at
3.8   TMEM163 223503_at
3.7   CTSB  227961_at involved in ECM degradation and apoptosis; overexpressed in 
several cancers
3.5   SCARB2 224983_at
3.4   PTGDS 211663_x_at
3.4   SERPING1  200986_at complement component C1 inhibitor
3.4   IGF2R  201392_s_at involved in tumor cell surveillance 
3.4   ALAS1 205633_s_at
3.4   SLC31A1 203971_at
3.3   RASGEF1A 230563_at
3.3   SLC26A11 226679_at
3.2   CTTN  201059_at oncogene; involved in tumor cell invasion and metastasis; 
overexpressed in several cancers
3.1   SCPEP1 218217_at
3  EOMES  231776_at transcription factor highly homologous to T-bet
3  RAB42 1552846_   
     s_at
member of the RAS oncogene family
3  C1orf54 219506_at
2.9   PLA2G2D 220423_at
2.9   LOC642705 228066_at
2.9   NPC1 202679_at
2.9   LMNA  203411_s_at lamin proteins are thought to be involved in nuclear stability 
and chromatin structure
2.9   EGR2 205249_at transcription  factor
2.9   FPR1  205119_s_at appears to mediate motility, growth and angiogenesis of human    
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in L  &  H cells. To quantify the B cell gene expression in each 
entity, we computed the fi  rst principal component of the ex-
pression matrix of the 61 B cell genes in GC B cells (representing 
high expression of B cell genes) and in CD4  +   and CD8  +   T 
cells (representing low expression of B cell genes). We then 
used the score displayed by each entity along this component 
as a measure of B cell gene expression and found it to be 
highly diff  erent across entities (10       9  using the Kruskal-Wallis 
test;   Fig. 3 B  ). L  &  H cells showed signifi  cantly reduced B cell 
gene expression compared with GC, na  ï  ve, and memory B 
cells. FL, BL, and DLBCL also showed signifi  cant B cell gene 
down-regulation compared with GC B cells, suggesting that 
this is a common feature among all of these GC B cell  –  de-
rived lymphomas. Nevertheless, the extent of B cell gene 
down-regulation in L  &  H cells is higher than in FL (P = 0.016) 
and in DLBCL and BL (although not reaching statistical sig-
nifi  cance). However, down-regulation of B cell markers in 
NLPHL is not as extensive as in cHL. 
  L  &  H cells show an antiapoptotic phenotype and create an 
immunosuppressive environment.     Comparing the genes dif-
ferentially expressed between L  &  H and GC B cells, 38 genes 
associated with apoptosis were identifi  ed (Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20080809/DC1), 
of which 28 were expressed at increased and 10 were expressed 
at decreased levels in L  &  H cells. All 21 genes with antiapop-
totic functions in the extrinsic and/or intrinsic apoptosis path-
way were expressed at increased levels in L  &  H cells, including 
and RAB7L1, are expressed at increased levels in L  &  H cells as 
compared with GC B cells. Besides the genes mentioned in 
this section, the analysis revealed several signaling pathways, 
survival mechanisms, and distortions of diff  erentiation pro-
grams that likely contribute to the pathogenesis of NLPHL, 
and they are presented in the following paragraphs. 
  L  &  H cells show a partial loss of their B cell phenotype.   
  To obtain a comprehensive overview about the expression of 
B cell markers in L  &  H cells, we selected informative probe 
sets for B cell markers known from the literature, as well as 
for genes we found in our profi  les to be up-regulated in nor-
mal B cells compared with CD4  +   and CD8  +   T cells. We thus 
generated a list of 61 B cell markers (94 informative probe 
sets). 60 out of the 61 genes showed statistically signifi  cantly 
reduced expression in L  &  H cells as compared with GC B cells, 
and only 1 gene,   IL21R  , was 2.2-fold up-regulated (  Fig. 3 A  ).   
The down-regulated B lineage  –  specific genes included B 
cell receptor signaling molecules like   CD79B  ,   CD22  ,   LYN  ,   
SYK  , and   BLNK  ; the transcriptional coactivator for Ig gene 
expression   POU2AF1   (  BOB1  ); the Fc receptor  –  like mole-
cules   FCRLA  ,   FCRL2   (  IRTA4  ), and   FCRL3   (  IRTA3  ); and 
the GC B cell  –  specifi  c transcription factors basic leucine zip-
per transcription factor 2 (  BACH2  ), IFN regulatory factor 8 
(  IRF8  ),   BCL6  , and   MYBL1   (  a-myb  )  .   Furthermore, transcription 
factors/modulators important for B cell development, lineage 
commitment, and maintenance, i.e., EBF, E2A, PAX5, Ikaros, 
BCL11A, and deltex 1 (DTX1), showed reduced expression 
    Table II.       L  & H  cell – specifi  c genes (Continued) 
FC Gene  
  symbol
Affymetrix  
  probe set ID
Gene function
2.7   PRKCZ  202178_at serine/threonine kinase; involved in proliferation and  
            differentiation; activates NF-     B
2.7   TPCN2 229250_at
2.6   ADFP 209122_at
2.5   SQSTM1 201471_s_at
2.4   VPS37C 219053_s_at
2.3   PNKD 233177_s_at
2.3   RTN4 214629_x_at
2.1   SLIC1 228869_at
2  ABCC1  202804_at involved in multidrug resistance
Genes down-regulated in NLPHL compared  
  with normal B cells and B-NHL
     2.3   CD79B 205297_s_at B  lineage  –  specifi  c gene
     3.8   BCNP1 230983_at B  lineage  –  specifi  c gene
     4.3   IGHM 209374_s_at B  lineage  –  specifi  c gene
     4/     4   TCL1A 39318_at B  lineage  –  specifi  c gene
209995_s_at
     2.8   FCRL2 1563674_at B  lineage  –  specifi  c gene
  49 genes specifi  cally up-regulated by L  &  H cells compared with normal and other malignant B cells were identifi  ed according to the following criteria: (a) expression 
above background level in   ≥  4 out of 5 L  & H  cell  profi  les and in   ≤  6 out of the 50 normal and other malignant B cell profi  les; and (b) greater than or equal to twofold 
up-regulation in L  &  H cells and with a   t   test p-value of   ≤  0.05. Five genes specifi  cally down-regulated in L  &  H cells were identifi  ed according to the following criteria: 
(a) expression above background level in   ≤  1 out of 5 L  &  H cell profi  les and in   ≥  33 out of the 50 normal and other malignant B cell profi  les; and (b) greater than or equal to 
twofold down-regulation in L  &  H cells and with a   t   test p-value   ≤  0.05. The 12 cHL profi  les were excluded from the comparison (see Results). For genes with known gene 
functions, these are indicated. 2258 NODULAR LYMPHOCYTE  –  PREDOMINANT HODGKIN LYMPHOMA   | Brune et al. 
17b (  STK17A   and   STK17B  ), and TNF receptor  –  associated 
factor 5 (  TRAF5  ; Fig. S4). The function of the remaining 
fi  ve proapoptotic genes (Fig. S4), expressed at increased lev-
els in L  &  H cells, may be inhibited by the increased expression 
of cystatin A and c-FLIP and the reduced expression of cas-
pase 2 (  33  –  35  ). 
cathepsin B, cystatin A (  CSTA  ), autotaxin, CD59, defender 
against cell death 1 (  DAD1  ), BAX inhibitor 1 (  TEGT  ), galec-
tin 3 (  LGALS3  ), peroxiredoxin 1 (  PRDX1  ), and   c-FLIP  . 
  10 out of the 15 proapoptotic genes were down-regu-
lated in L  &  H cells, including caspase 2 (  CASP2  ), Ataxia telan-
giectasia mutated (  ATM  ), serine/threonine kinases 17a and 
    Figure 3.         Partial loss of B cell markers in NLPHL.   (A) Heat map of the absolute expression values of B cell markers, which are encoded by the color 
bar (base 2 logarithmic scale). (B) Individual samples (squares) are placed along the fi  rst principal component (which accounts for 92.2% of the total vari-
ance) of the expression matrix of 61 selected B cell markers. Box plots summarize the score of each group in this component. The vertical lines ending in 
horizontal lines (whiskers) extend to the most extreme data points if they extend not more than 1.5 times the box width (the interquartile range). Other-
wise, the whiskers end at an observed value that is not more than 1.5 times the box width away from the box. p-values of the pairwise comparisons using 
a Wilcoxon test are indicated.     JEM VOL. 205, September 29, 2008 
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with published data, NF-     B activity is low in FL and BL and 
highly diverse in DLBCL (  43, 44  ). Approximately half of the 
DLBCLs (including DLBCLs 2, 3, and 11, which show some 
similarity with NLPHL;   Fig. 1   and Fig. S3) show expression 
of most NF-     B target genes. TCRBLs also seem to have 
strong NF-     B activity in most cases. To quantify NF-     B ac-
tivity across diff  erent entities, we computed the fi  rst principal 
component of the expression matrix of NF-     B target genes 
in HRS cells (representing high NF-     B activity) and GC B 
cells (representing low NF-     B activity). We then used the score 
displayed by each entity along this component as a measure 
for NF-     B activity and found it to be highly diff  erent across 
entities (3       10       9  using the Kruskal-Wallis test;   Fig. 4 B  ). 
NLPHL shows the strongest NF-     B activity in this PCA, with 
high statistical signifi  cance compared with GC B cells, FL, BL, 
and DLBCL, and with a trend also compared with cHL and 
TCRBL (  Fig. 4 B  ). 
  To confi  rm NF-     B expression and activity in L  &  H cells, 
we performed immunohistochemistry with an antibody rec-
ognizing an epitope that is only accessible when NF-     B hetero-
dimers contain active p65 (  45  ). In 19 out of the 19 cases of 
NLPHL analyzed, strong p65 staining was observed in L  &  H 
cells (  Fig. 5 A  ).   Collectively, L  &  H cells show a strong consti-
tutive NF-     B activity and increased expression of the vast 
majority of NF-     B target genes in our study. 
  Extracellular signal-regulated kinase (ERK) activation plays 
a role in at least a proportion of NLPHL cases.     We identi-
fi  ed several genes up-regulated in L  &  H cells compared with 
GC B cells that indicate activation of the ERK pathway. 
This pathway is implicated in malignant transformation and the 
regulation of cellular growth and proliferation. KISS1 receptor 
(10.4-fold up-regulated), galectin 1 (4.5-fold up-regulated), 
chitinase 3  –  like 1 (  CHI3L1  ; 36.3-/20.4-fold up-regulated), 
  In addition, the L  &  H cells have acquired several mecha-
nisms to escape from immune surveillance by T and NK cells. 
The galectins 1, 2, and 3, which are all up-regulated in L  &  H 
cells (Fig. S4), can mediate proapoptotic signals to neighbor-
ing T cells and could thereby counteract the elimination of 
L  &  H cells by T cells (  36  ). Cathepsin B cleaves perforin (  37  ), 
and secreted IGF2R/M6PR acts as a sink for granzyme B 
  secreted by CD8  +   cytotoxic T cells (  38  ). MMP9, which is 
strongly up-regulated in L  &  H cells (  Table III  ), participates in 
resistance to NK cell  –  mediated cytotoxicity (  39  ).   Diff  erent 
MHC I molecules are up-regulated between two- and fi  ve-
fold in L  &  H cells (unpublished data), which may prevent 
the elimination of these cells by NK cells. CD59 (3.6-fold 
up-regulated) inhibits the formation of the membrane attack 
complex. Additionally, soluble annexin A2 (sixfold up-regu-
lated) has immunosuppressive properties (  40  ). Collectively, 
survival of the L  &  H cells seems to be promoted by the up-
regulation of multiple antiapoptotic genes, the down-regula-
tion of numerous proapoptotic genes, and the creation of an 
immunosuppressive environment. 
  L  &  H cells are characterized by a strong constitutive NF-     B 
activity.     Among the genes diff  erentially expressed between 
L  &  H and GC B cells, numerous NF-     B target genes were 
observed. To study NF-     B activity in L  &  H cells in more de-
tail, we generated a comprehensive list of 62 informative probe 
sets for 50 NF-     B target genes (  Fig. 4  ).   GC B cells showed 
no signifi  cant expression of the NF-     B target genes, and HRS 
cells had strong expression, as expected (  41, 42  ). Thus, this 
list of NF-     B target genes is well suited to discriminate cases 
with and without NF-     B activity. Strikingly, 48 out of 50 
genes showed a strong expression by L  &  H cells, at levels com-
parable to HRS cells, and only 2 genes (  CCL22   and   IL6  ) 
showed signal intensities below background (  Fig. 4 A  ). In line 
    Table III.        Immunohistochemical expression of genes with higher transcript levels in L  &  H than in GC B cells 
Gene name Affymetrix probe set ID FC up-regulation in L  &  H  
  cells versus GC B cells
Positivity in primary  
  NLPHL cases (%)    a   
Positivity in GC B cells
  CTSB  200839_s_at 44.7 19/19 (100) faint background staining
200838_at 14.6
213274_s_at 14.3
213275_x_at 14.1
227961_at 6.2
  MMP9  203936_s_at 60.2 15/16 (94) faint background staining
  MMP12  204580_at 25.4 15/17 (88) faint background staining
  LGALS3 208949_s_at 25.8 15/15  (100) negative
  IL21R 221658_s_at 2.2 7/7  (100) positive
  EOMES 231776_at 4.1 10/15  (67) negative
  p-STAT1 209969_s_at 17.7 (STAT1     ) 11/19 (58) negative
200887_s_at 8.7 (STAT1     )
AFFX-HUMISGF3A/  
              M97935_3_at
6.4 (STAT1     )
  a  A case was scored as positive if   ≥  20% of L  &  H cells showed expression of the respective marker. For CTSB, MMP9, MMP12, LGALS3, and IL21R, the vast majority of L  & H  cells 
were positive. Positivity for the expression of EOMES and p-STAT1 in L  &  H cells ranged from 20  –  80%. p-STAT1 was detected in a fraction of L  &  H cells in 11 out of 19 cases of 
NLPHL, which might underestimate the frequency of positive cases for reasons discussed regarding p-ERK staining.2260 NODULAR LYMPHOCYTE  –  PREDOMINANT HODGKIN LYMPHOMA   | Brune et al. 
    Figure 4.         NF-    B activity in NLPHL.   The list of NF-     B target genes experimentally validated in cHL cell lines (reference   89  ) was expanded by including other 
NF-     B target genes described in the literature or other sources (available at http://www.nf-kb.org). After excluding all noninformative probe sets (signals below 
background in all samples), we obtained a list of 62 probe sets, corresponding to 50 NF-     B target genes, of which 48 turned out to be consistently up-regulated in 
L  &  H versus GC B cells (FDR   <   0.05 after   t   test; FC   ≥   1.8). (A) Heat map of NF-     B target genes. The sources of the NF-     B target genes are (1) http://www.nf-kb.org, 
(2) the literature, and (3) Hinz et al. (reference   89  ), as indicated in parentheses after the gene names. The absolute expression values on a logarithmic scale (base 2) 
are encoded by the color bar. (B) Individual samples (squares) are placed along the fi  rst principal component (which accounts for 80.1% of the total variance) of 
the expression matrix of 50 NF-     B target genes. Box plots summarize the scores displayed by each group in this component. The vertical lines ending in horizontal 
lines (whiskers) extend to the most extreme data points if they extend not more than 1.5 times the box width (the interquartile range). Otherwise, the whiskers end 
at an observed value that is not more than 1.5 times the box width away from the box. p-values of the pairwise comparisons using a Wilcoxon test are indicated.    
SLAM family member 7 (13.9-fold up-regulated), and syn-
decan binding protein (  SDCBP  ; 2.6-fold up-regulated) acti-
vate ERK (  46  –  50  ). RAS homologue gene family member H 
(  RHOH  ), which is 2.3-fold down-regulated, was previously 
described to suppress ERK activation ( 51  ).  PLAU   (9.1-fold up-
regulated) is an ERK target gene as well as a major determinant JEM VOL. 205, September 29, 2008 
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Because   STAT1   can be phosphorylated by ERK and thereby 
activated (  60  ), we stained NLPHL for p-STAT1 and revealed 
nuclear localization of p-STAT1 in a fraction of L  &  H cells in 
more than half of the cases (  Fig. 5 J  ). Thus, the frequent de-
tection of p-ERK, together with the increased expression of 
numerous ERK activating and target genes, indicates a de-
regulated activation of this signaling pathway in L  &  H cells. 
  Extracellular matrix (ECM) degradation and tissue re-
modeling.     L  &  H cells turned out to express a large number of 
ECM-degrading molecules, including MMP9, MMP12, and 
several cathepsins, at higher levels than GC B cells and at 
similar or higher levels than the more aggressive DLBCL and 
BL (Fig. S5, available at http://www.jem.org/cgi/content/
full/jem.20080809/DC1). This was unexpected given the 
indolent behavior of NLPHL, and the correlation in B-NHL 
of ERK activation (  52  ). Furthermore, several additional tran-
scriptional targets of the ERK pathway, namely   DR5  ,   STAT3  ,   
MMP9  ,   CDKN1A   (  p21  CIP1/WAF1    ), and cathepsin B (  53  –  57  ), 
are up-regulated in L  &  H cells. Four out of the six are also NF-
     B target genes (  Fig. 4 A  ). 
  To determine whether L  &  H cells aberrantly express acti-
vated ERK, we performed immunohistochemical staining of 
paraffi   n sections of NLPHL and normal tonsils using anti-
bodies against total ERK and phosphorylated ERK (p-ERK). 
As previously reported (  58  ), normal GC B cells were ERK 
positive, but p-ERK was not detectable (unpublished data). 
Among NLPHL, 10 out of 14 cases expressed ERK, and 4 
out of 12 cases were positive for p-ERK in a fraction of L  &  H 
cells (  Fig. 5, B and C  ). The true fraction of cases with acti-
vated p-ERK is likely higher because of a loss of phospho-
groups caused by insuffi   cient preservation of material (  59  ). 
    Figure 5.         Protein expression in NLPHL cases.   (A – J)  Immunohistological  stainings  of  paraffi  n sections of lymph nodes from patients with NLPHL for 
active NF-     B p65 subunit (A), total ERK (B), active p-ERK (C), CTSB (D), MMP9 (E), MMP12 (F), LGALS3 (G), IL21R (H), EOMES (I), and p-STAT1 (J). The anti  –
 NF-    B p65 antibody recognizes only p65 that is no longer bound by I     B factors, and thus identifi  es active NF-     B factors, although the staining appears 
often predominantly cytoplasmatic (reference   45  ). Insets show L  &  H cells at higher magnifi  cation. Some insets (A, B, D, E, G, and J) are magnifi  ed using 
Photoshop CS software (Adobe). Bars, 10   μ  m.     2262 NODULAR LYMPHOCYTE  –  PREDOMINANT HODGKIN LYMPHOMA   | Brune et al. 
  L  &  H and HRS cells are very similar in their 
gene expression patterns 
  NLPHL and cHL are classifi  ed as two subtypes of HL, and 
several genes were already identifi  ed as being aberrantly ex-
pressed by both L  &  H and HRS cells (  18, 23, 24  ). However, 
several studies stressed many clinical, phenotypic and genetic 
diff  erences between L  &  H and HRS cells and also pointed to 
distinct histogenetic origins of the tumor cells (  1, 3, 4, 62  ). 
On this background, it was unexpected to fi  nd only a few 
genes diff  erentially expressed between L  &  H and HRS cells. 
Our approach is, however, partly underestimating the diff  er-
ences between L  &  H and HRS cells, as HRS cells may be 
quite heterogeneous in gene expression, and we focused on 
genes with consistent diff  erential expression. Many of the 
phenotypic diff  erences between L  &  H and HRS cells seen in 
our analysis and also described in the literature (  4, 26, 63, 64  ) 
are related to the strong down-regulation of B cell markers in 
HRS cells, which is not as extensive in L  &  H cells (discussed 
in the third following section). Nevertheless, we identifi  ed a 
few additional diff  erences in the gene expression of L  &  H and 
HRS cells (  Table I  ). Future studies should reveal which of 
the diff  erences refl  ect or are responsible for distinct patho-
genetic mechanisms in NLPHL and cHL. 
  Based on many similarities in their histological picture 
(a nodular growth pattern, and an association with CD57  +  CD4  +   
GC T helper cells and follicular dendritic cells), the pheno-
type of the lymphoma cells (CD20  +  , BCL6  +  , activation-in-
duced cytidine deaminase  +  , centerin  +  , human GC-associated 
lymphoma  +  ), and genetic features (selection for functional IgV 
genes and ongoing somatic hypermutation), one might have 
expected that L  &  H cells are actually more similar to FL cells 
than to HRS cells. However, our study shows that at the level 
of global gene expression, L  &  H cells are much more closely 
related to HRS than to FL cells. 
  Only a few genes distinguish L  &  H cells 
and the lymphoma cells of TCRBL 
  L  &  H cells turned out to be most closely related to the neo-
plastic cells of TCRBL and a subgroup of DLBCL, thus ex-
panding on a genome-wide view of the reported biological, 
phenotypical, and clinical relatedness of these lymphomas. 
Despite their morphological and phenotypical similarities, 
the clinical presentation and treatment strategies of TCRBL 
and NLPHL are diff  erent. Therefore, the diff  erential diagno-
sis between NLPHL and TCRBL has important therapeutic 
implications. So far, only the transcription factor PU.1 has 
been reported to be expressed more frequently in L  &  H cells 
than in the lymphoma cells of TCRBL. We identifi  ed 42 dif-
ferentially expressed genes (Fig. S2 and Table S1) that might 
be suitable for establishing new immunohistochemical mark-
ers for diff  erential diagnosis. 
  L  &  H cells resemble GC B cells at the transition 
to memory B cells 
  Although L  &  H cells clearly resemble GC B cells in many 
phenotypic and genetic aspects, their gene expression profi  le 
between expression levels of ECM-degrading molecules and 
clinical aggressiveness (  61  ). Besides a role for tissue remodeling 
in NLPHL, up-regulation of these genes may have other func-
tions in L  &  H cells, such as inactivation of apoptosis-inducing 
perforin by cathepsin B (  37  ). 
  Validation of protein expression in primary NLPHL cases 
  To further validate the reliability of our analysis and to verify 
whether the up-regulated mRNA levels in L  &  H cells corre-
spond to elevated protein levels, we investigated NLPHL and 
reactive tonsils for protein expression of cathepsin B, MMP9, 
MMP12, galectin 3, p-STAT1, EOMES, and IL21R by im-
munohistochemistry, as suitable antibodies were available and 
as these molecules may be of pathogenetic relevance (  Fig. 5, 
D  –  J  ). With the exception of IL21R (see Discussion), normal 
tonsillar GC B cells showed no or only weak background 
staining for these markers, as expected (  Table III  ). All of the 
markers tested showed consistent and often strong expression 
in L  &  H cells in most or even all NLPHLs analyzed (  Table III  ). 
Although the Aff  ymetrix data indicated only a twofold up-
regulation of IL21R transcripts in L  &  H cells versus GC B cells, 
in some NLPHL cases we detected stronger staining in L  &  H 
cells than in the infi  ltrating lymphocytes. Overall, the results 
of the immunohistochemical stainings confi  rmed the up-regu-
lated expression of these genes in L  &  H cells compared with GC 
B cells in the great majority of cases. 
    DISCUSSION   
  Gene expression profi  ling of microdissected lymphoma cells 
  As the present work represents one of the fi  rst global tran-
scriptome studies with microdissected lymphoma cells, the 
reliability of the results obtained is a critical issue. Certainly, 
when microdissecting L  &  H cells from tissue sections, a low 
level contamination with RNA from rosseting CD4  +   T cells 
cannot be excluded. However, for several reasons it is evi-
dent that the results obtained in the present analysis are not 
compromised by such a contamination. First, the immuno-
histochemical study of genes identifi  ed in the comparison 
of microdissected L  &  H cells and cytometrically isolated GC 
B cells revealed that all markers were indeed consistently ex-
pressed in L  &  H cells (  Table III   and   Fig. 5  ). Second, several 
typical markers of activated CD4  +   T cells (e.g., GATA3, 
CTLA4, and IL7-R), which were clearly detected in tonsil-
lar-activated CD4  +   T cells, gave signals only in the range of 
the background noise in L  &  H cells (unpublished data). Third, 
CD4  +   T cells do not show an NF-     B signature (unpublished 
data), ruling out that the strong NF-     B signature detected in 
L  &  H cells could derive from contaminating T cells. Finally, 
a low level contamination with RNA from T cells should 
furthermore largely be averaged out in the diff  erential gene 
expression studies, as T cells are also surrounding the other 
lymphoma cells microdissected as single cells (lymphoma cells 
from cHL and TCRBL), and T cells are also present at low 
frequency in the lymphoma microenvironment of the lym-
phomas in which lymphoma cell  –  rich areas were microdis-
sected (DLBCL, FL, and BL). JEM VOL. 205, September 29, 2008 
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B cell receptors, rendering this concept unlikely for NLPHL. 
Moreover, L  &  H cells still express many genes at immuno-
histochemically detectable levels, and they are closely associated 
with normal constituents of GC, indicating microenviron-
mental interactions like those of normal GC B cells. There-
fore, it appears that (some) B cell functions are still essential 
for the survival and proliferation of those cells. Perhaps the 
diminished expression and/or function of B cell genes in L  &  H 
cells is a side eff  ect of the so far largely unknown transforming 
event in these cells. Indeed, for   PAX5  , mutations were recently 
described in L  &  H cells, although their functional consequences 
are still unclear (  14  ). 
  Identifi  cation of L  &  H cell  –  specifi  c genes 
  We identifi  ed 49 genes as being signifi  cantly up-regulated 
in L  &  H cells in comparison to normal B cells and B-NHL. 
By immunohistochemistry, we showed protein expression of 
MMP12, CTSB, and EOMES (  Fig. 4  ) in L  &  H cells of pri-
mary NLPHL, thereby confi  rming our microarray data. In-
deed, the genes showing deregulated expression in L  &  H cells 
may represent interesting new diagnostic markers and might 
be of special interest for the pathogenesis of NLPHL. Protein 
kinase C       is involved in cell growth, proliferation, and dif-
ferentiation, as well as in the activation of NF-     B (  68  ). KISS1 
receptor activates ERK signaling (  46  ). High levels of ubiqui-
tin D (UBD) were shown to increase mitotic nondisjunction 
and chromosome instability promoting tumorigenesis (  69  ). 
Up-regulated UBD in L  &  H cells might therefore contribute 
to chromosomal abnormalities in NLPHL. 
  L  &  H cells show deregulation of apoptosis regulators 
  L  &  H cells show up-regulated expression of genes encoding 
antiapoptotic molecules and down-regulation of most pro-
apoptotic genes. The pattern is not only a characteristic fea-
ture of L  &  H cells in comparison to the apoptosis-prone GC 
B cells, but also in comparison to the other normal B cell 
subsets, indicating a tumor-specifi  c deregulation of mole-
cules regulating apoptosis (Fig. S4). Notably, HRS cells and 
most TCRBLs and DLBCLs show a similar expression pat-
tern of pro- and antiapoptotic genes as L  &  H cells, whereas 
FLs and BLs behave diff  erently in this regard. This indicates 
similar pathogenic mechanisms in NLPHLs, TCRBLs, and 
some DLBCLs to escape apoptosis, further supporting the 
similarity of these malignancies. 
  L  &  H cells are characterized by a strong constitutive 
NF-    B activity 
  Constitutive NF-     B activity is involved in deregulated prolif-
eration, malignant transformation, and resistance to apoptosis 
in a variety of tumors, including cHL (  70  ). In previous studies, 
active RelA was detected in L  &  H cells in a small collection of 
6 NLPHL cases (  71  ), and cREL was found in only 3 out of 15 
NLPHLs (  72  ). These studies did not address whether these 
NF-     B factors indeed cause expression of NF-     B target genes. 
To clarify this, we analyzed the expression of a large set of NF-
     B target genes in L  &  H cells and found it to be at least as high 
(  Fig. 2 B  ) suggests that they might originate from transformed 
late GC B cells in the process of diff  erentiation toward mem-
ory B cells. This hypothesis would be consistent with our 
fi  nding of constitutive NF-     B activity in L  &  H cells, as a sub-
set of centrocytes in the GC light zone presumably develop-
ing toward memory B cells shows active NF-     B, whereas the 
majority of GC B cells lacks NF-     B activity (  41  ). However, 
it cannot be excluded that NF-     B activation is acquired after 
neoplastic transformation of a GC B cell into a L  &  H cell, thus 
being unrelated to the cell of origin of NLPHL. 
  L  &  H cells show a partial loss of their B cell phenotype 
  Previous immunohistochemical studies reported that L  &  H 
cells usually express general B cell markers and GC B cell  –
  specifi  c molecules (  3  –  6, 26, 62  –  64  ). However, at the level 
of sensitivity of immunohistochemistry, L  &  H cells also lack 
expression of some B lineage markers (  65  ). These data are, 
however, not quantitative and are restricted to a relatively 
small number of proteins. Analyzing a comprehensive set 
of 61 B lineage  –  specifi  c genes, we identifi  ed 60 genes that 
were not expressed or transcribed at reduced levels in L  &  H 
cells in comparison to normal GC B cells, including many 
already described. 
  As plasma cells down-regulate many B cell genes, it has to 
be considered whether the low expression of multiple B cell 
genes refl  ects a (partial) diff  erentiation of L  &  H cells or their 
precursors toward a plasma cell phenotype. However, the PCA 
suggested that L  &  H cells are more similar to GC and mem-
ory B cells than to plasma cells. Moreover, for key plasma cell 
markers (i.e., BLIMP1, XBP1, and CD38), the expression 
levels of L  &  H cells were similar to the ones of GC B cells and 
lower than in plasma cells (unpublished data). Thus, the down-
regulated B cell phenotype of L  &  H cells cannot be explained 
by a plasma cell diff  erentiation. 
  The diminished expression of the B cell  –  specifi  c transcrip-
tion factors PAX5, E2A, EBF, Ikaros, and BCL11A, and of 
the Notch1 inhibitor deltex 1, is likely to result in a reduced 
expression of multiple B cell genes and, hence, is presumably 
a major cause of the partial loss of the B cell phenotype in L  &  H 
cells. Furthermore, the aberrant expression of ID2, a negative 
regulator of E2A, in L  &  H cells (  66  ) may also contribute to the 
diminished expression of several B lineage  –  specifi  c genes in 
these cells. This could also be caused by epigenetic silencing, 
but promoter methylation does not explain the loss of ex-
pression of CD10, CD19, or LCK in L  &  H cells (  65  ). 
  Only a single B cell  –  associated gene,   IL21R  , was up-
regulated in L  &  H cells, and it also showed a tendency for in-
creased expression at the protein level. As follicular T helper 
cells are the main producers of IL21 and as IL21R triggering 
improves the survival of normal GC B cells, sustained IL21R 
expression may be important for the survival of L  &  H cells 
and their interaction with surrounding T helper cells (  67  ). 
  In cHL, the global loss of the B cell phenotype may be 
of selective advantage for the HRS (precursor) cells to es-
cape the apoptotic program in GC B cells with destructive 
IgV mutations (  2  ). However, L  &  H cells express functional 2264 NODULAR LYMPHOCYTE  –  PREDOMINANT HODGKIN LYMPHOMA   | Brune et al. 
  MATERIALS AND METHODS 
  Purifi  cation of normal B cell subsets and selection 
of lymph node biopsies of lymphoma patients 
  Naive and memory B cells were isolated from the peripheral blood of fi  ve 
healthy adult donors. Tonsils for the isolation of centrocytes, centroblasts, and 
plasma cells were obtained from patients undergoing routine tonsillectomy. 
Approval by the Internal Review Board in Essen for these studies was ob-
tained. Tonsils and blood samples were immediately cooled at 0  –  4  °  C, and cells 
were further processed and immediately sorted after staining at this low tem-
perature to avoid changes in gene expression caused by RNA turnover or sig-
naling eff  ects of the antibodies used for staining. 2,000 naive B cells were 
isolated by magnetic cell separation, depleting CD27  +   (memory B cells, T cell 
subpopulation) and CD11b  +   (monocytes, macrophages, granulocytes, NK 
cells) cells, using the MACS system (Miltenyi Biotec), followed by FACS sort-
ing of IgD  +   CD27         cells. 2,000 memory B cells were isolated by MACS de-
pletion of CD11b  +   and CD3  +   cells, followed by FACS sorting of CD20  +   
CD27  +   cells. 2,000 tonsillar GC B cells and plasma cells were isolated by FACS 
sorting according to the following marker expression: CD20  high   CD38  +   CD77  +   
(centroblasts), CD20  high   CD38  +   CD77         (centrocytes), and CD20  low   CD38  high   
(plasma cells). We used CD77 to separate centroblasts and centrocytes. How-
ever, it has meanwhile become clear that this marker is unsuitable to clearly 
separate the two GC B cell subsets for gene expression studies (  77, 78  ). 
  As human transitional B cells have recently been identifi  ed as CD20  +   
CD38  +   IgD  +   peripheral blood B cells (  79  ), the isolated GC B cells might 
potentially be contaminated by transitional B cells. However, as only 5  –  15% 
of GC B cells express IgD and at least half of these are GC founder cells with 
mutated V genes (  80  ), transitional B cells could account at most for     5% of 
sorted GC B cells. Importantly, transitional B cells also express CD5  +  , and 
tonsillar CD20  +   CD38  +   IgD  +   CD5  +   B cells were found to lack CD77 ex-
pression (  79, 81  ). Thus, our sorted CD77  +   GC centroblast population is de-
void of transitional B cells, and as there are no signifi  cant diff  erences in gene 
expression between CD77  +   and CD77         tonsillar GC B cells (  77, 78  ), we 
also conclude that the gene expression profi  le of CD77         centrocytes is not 
signifi  cantly contaminated by RNA from transitional B cells. 
  The total RNA of all lymphoma cases was isolated from frozen tissue 
sections with TRI  zol   (Invitrogen), followed by RNeasy Mini Kit column 
purifi  cation (QIAGEN) to check RNA quality with a 2100 Bioanalyzer 
Nano Assay (Agilent Technologies). Among the cases with good RNA qual-
ity (28S/18S ratio   >   1.5; no signs of degradation in the electropherogram), 
5 cases of NLPHL, 12 cases of cHL, 4 cases of TCRBL, 11 cases of DLBCL, 
5 cases of FL, and 5 cases of BL, diagnosed according to the World Health 
Organization classifi  cation, were selected for gene expression profi  ling. One 
out of the fi  ve NLPHLs (NLPHL3) was microdissected from a lymph node 
taken at relapse; in another area of the lymph node, a transformation to 
DLBCL was observed, which was not present in the lymph node taken at 
disease onset and which was also subjected to microdissection and gene 
  expression profi  ling (representing 1 out of the 11 DLBCLs mentioned, 
DLBCL3). For the analysis of B cell gene expression, we used an additional 11 
profi  les from human tonsillar CD4  +   and CD8  +   T cells that will be published 
as part of a future study. 
  Microdissection of lymphoma cells 
  5-  μ  m-thick frozen sections of lymph nodes from lymphoma patients were 
mounted on membrane-covered slides (PALM), incubated with hematoxylin 
containing 200 U/ml RNase inhibitor (Roche) for 4 min, washed in molecu-
lar biology grade water for 2 min, incubated in 2% eosin for 15 s, washed 
again, and dried at 37  °  C for 3 h. Microdissection was performed using the la-
ser microdissection and pressure catapulting (LMPC) technique with a UV la-
ser beam (PALM). cHL, NLPHL, and TCRBL tumor cells were microdissected 
as single cells according to their characteristic morphological criteria concern-
ing nuclear shape and diameter, chromatin distribution, nucleoli, and the 
amount and density of cytoplasm. In DLBCL, FL, and BL cases, areas with at 
least 95% tumor cells were selected so that these tumor cells could be micro-
dissected in areas. Cells were directly catapulted into lysis buff  er (Purescript; 
Gentra) and pooled in groups of 1,000  –  2,000 tumor cells. 
as in HRS cells (  Fig. 4  ). Strong immunostaining for the active 
form of p65 in L  &  H cells in 19 out of 19 NLPHLs (  Fig. 5 A  ) 
further confi  rms constitutive NF-     B activity in L  &  H cells. 
  The mechanisms underlying the strong NF-     B activity in 
L  &  H cells are still unclear. Genomic gains of the   REL   gene, as 
frequently seen in cHL, are presumably not involved, because 
L  &  H cells rarely show active c-REL (  72  ). A contribution 
by EBV, as in cHL, does not play a role in NLPHL, as L  &  H 
cells are virtually never EBV infected. Remarkably, whereas 
T cells rosetting around HRS cells in cHL frequently express 
CD40L and may thus cause NF-     B activation by triggering 
CD40 on the HRS cells, rosetting T cells surrounding L  &  H 
cells rarely express CD40L, rendering a contribution of this 
signaling pathway in L  &  H cells also unlikely (  73  ). Whether 
inactivating mutations of the I     B      or the I     B      genes as in 
cHL are involved in the pathogenesis of NLPHL remains to 
be clarifi  ed. 
  Implications for NLPHL pathogenesis, treatment, 
and diagnosis 
  The present work revealed important novel insights into 
the nature and pathogenesis of the L  &  H cells in NLPHL. 
Although L  &  H cells clearly resemble GC B cells in many 
phenotypic and genetic aspects, their gene expression profi  le 
seems to place them at the transition of GC B cells to mem-
ory B cells. We identifi  ed several pathogenetic mechanisms 
in NLPHL, including strong constitutive activity of NF-     B 
and activation of the ERK signaling pathway. Activation 
of the ERK pathway is critical for a large number of Ras-
induced cellular responses and has been implicated in the 
pathogenesis of several cancers. Its aberrant activation in L  &  H 
cells was previously unknown and might be of pathogenic 
relevance. Several pharmacological agents that inhibit NF-     B 
or ERK are currently under clinical investigations (  74, 75  ) and 
may become suitable for therapy in NLPHL. Further patho-
genetic mechanisms in NLPHL involve the suppression of 
apoptosis and the creation of an immunosuppressive environ-
ment to escape from immune surveillance. The role of other 
genes that emerged to be specifi  cally deregulated in L  &  H cells 
requires further investigation. 
  Because HRS and L  &  H cells show marked diff  erences in 
immunohistochemical analysis (  1, 62  ), their close relatedness 
in terms of gene expression profi  le appears surprising. Simi-
larities among these tumor cells include constitutive NF-     B 
activity and ERK signaling, which suggest that NLPHL and 
cHL may share similar pathogenetic mechanisms. The gene 
expression profi  le of HRS and L  &  H cells also resemble each 
another because of down-regulation of B lineage  –  specifi  c 
genes, although this event is not as severe in L  &  H cells as in 
HRS cells. L  &  H cells turned out to be even more similar to 
TCRBL (and a subset of DLBCL) in terms of gene expression. 
Because the distinction between NLPHL and TCRBL is, 
however, clinically important (  76  ), the genes discriminating 
between L  &  H cells and TCRBL identifi  ed in this paper may 
become valuable markers for the diff  erential diagnosis of 
NLPHL and TCRBL. JEM VOL. 205, September 29, 2008 
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the stability of the resulting dendrogram, we used Pvclust (  87  ), an R soft-
ware package for assessing the uncertainty in hierarchical cluster analysis. 
  Heat map.     A heat map is a false color display of a matrix of numerical val-
ues. Heat maps were generated with Spotfi  re software (Spotfi  re DecisionSite 
9.1, 1996  –  2007). 
  Diff  erential gene expression.     Many of the genes on the microarray are 
not expressed in most of the samples or have only a small variability across 
the samples. For each pairwise comparison, we fi  rst used a global fi  lter to re-
duce the dimension of the microarray data. We applied an intensity fi  lter 
(the signal intensity of a probe set should be   >  100 in at least 25% of the sam-
ples if the group sizes are equal) and a variance fi  lter (the interquartile range 
of log2 intensities should be at least 0.5 if the group sizes are equal). If the 
group sizes are not equal, the signal intensity of a probe set should be   >  100 
in at least a fraction       of the samples, where       is the smaller group size minus 
one, divided by the total sample size of the two groups. 
  The interquartile range of log2 intensities should be at least 0.1 if the 
group sizes are not equal. After the global fi  ltering, we applied the two-sam-
ple   t   test (assuming equal variance in both groups) to identify genes that are 
diff  erentially expressed between the two groups. To account for the multiple 
testing, we used the FDR, as described by Benjamini and Hochberg (  88  ). In 
addition, FC values between the two groups were calculated for each gene. 
Diff  erentially expressed genes were determined with FDR and FC criteria. 
  PCA.     For preselected gene sets and predecided groups of samples, we used 
PCA analysis. The fi  rst principal component is used as an expression signa-
ture for the given gene set, which is then applied to the samples of all 
groups. A Wilcoxon test was performed to detect signifi  cant diff  erences 
between the groups after PCA. 
  Online supplemental material 
  Fig. S1 shows an unsupervised hierarchical clustering of all normal and ma-
lignant samples analyzed. Fig. S2 shows a heat map of 42 genes diff  erentially 
expressed between L  &  H cells and TCRBL. Fig. S3 shows a heat map of 
genes diff  erentially expressed between L  &  H cells and all other normal and 
neoplastic samples. Fig. S4 shows a heat map of apoptosis-associated genes 
that show a signifi  cantly diff  erent expression in L  &  H cells compared with 
GC B cells. Fig. S5 shows a heat map for the expression of genes associ-
ated with ECM degradation and tissue remodeling in normal and neoplastic 
B cells. Table S1 lists the genes diff  erentially expressed between L  &  H cells 
and TCRBL. Table S2 provides the conditions for immunohistochemistry. 
Online supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20080809/DC1. 
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